Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients

Leukemia Research

Volumn 32, Issue 11, 2008, Pages 1653-1660

  Lee, Je Jung ^a   Choi, Bo Hwa ^a   Kang, Hyun Kyu ^a   Kim, Sang Ki ^a   Nam, Jong Hee ^a   Yang, Deok Hwan ^a   Kim, Yeo Kyeoung ^a   Kim, Hyeoung Joon ^a   Chung, Ik Joo ^a  

^a Chonnam National University   (South Korea)

Author keywords

Acute myeloid leukemia; Allogeneic immunotherapy; Dendritic cells

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 12;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC MONOCYTE DERIVED DENDRITIC CELL; ARTICLE; BLOOD DONOR; CELL THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA MATCHING; HUMAN; LEUKEMIA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN-12; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MONOCYTES; PHENOTYPE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DONORS;

EID: 48949107709     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.038     Document Type: Article

References (32)

1. Estey E., and Dohner H. Acute myeloid leukaemia. Lancet 368 9550 (2006) 1894-1907
2. Kolitz J.E. Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol 134 6 (2006) 555-572
3. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 5 (1995) 2041-2050
4. Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., and O'Reilly R.J. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?. Bone Marrow Transplant 15 4 (1995) 591-594
5. Buzyn A., Petit F., Ostankovitch M., Figueiredo S., Varet B., Guillet J.G., et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 94 9 (1999) 3135-3140
6. Hirano N., Takahashi T., Takahashi T., Ohtake S., Hirashima K., Emi N., et al. Expression of costimulatory molecules in human leukemias. Leukemia 10 7 (1996) 1168-1176
7. Notter M., Willinger T., Erben U., and Thiel E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 97 10 (2001) 3138-3145
8. Buggins A.G., Lea N., Gaken J., Darling D., Farzaneh F., Mufti G.J., et al. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood 94 10 (1999) 3479-3490
9. Houtenbos I., Westers T.M., Ossenkoppele G.J., and van de Loosdrecht A.A. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica 91 3 (2006) 348-355
10. Choudhury B.A., Liang J.C., Thomas E.K., Flores-Romo L., Xie Q.S., Agusala K., et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93 3 (1999) 780-786
11. Harrison B.D., Adams J.A., Briggs M., Brereton M.L., and Yin J.A. Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood 97 9 (2001) 2764-2771
12. Waclavicek M., Berer A., Oehler L., Stockl J., Schloegl E., Majdic O., et al. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Br J Haematol 114 2 (2001) 466-473
13. Kang H.K., Park J.S., Kim S.K., Choi B.H., Pham T.N., Zhu X.W., et al. Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. Leuk Lymphoma 47 10 (2006) 2224-2233
14. Wang S., Hong S., Yang J., Qian J., Zhang X., Shpall E., et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108 13 (2006) 4071-4077
15. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6 5 (2000) 1755-1766
16. Hasebe H., Nagayama H., Sato K., Enomoto M., Takeda Y., Takahashi T.A., et al. Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother 54 6 (2000) 291-298
17. Mohty M., Jarrossay D., Lafage-Pochitaloff M., Zandotti C., Briere F., de Lamballeri X.N., et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98 13 (2001) 3750-3756
18. Xu F., Ye Y.J., Cui Z.R., and Wang S. Allogeneic dendritomas induce anti-tumour immunity against metastatic colon cancer. Scand J Immunol 61 4 (2005) 364-369
19. Marten A., Renoth S., Heinicke T., Albers P., Pauli A., Mey U., et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14 5 (2003) 483-494
20. Santegoets S.J., Schreurs M.W., Masterson A.J., Liu Y.P., Goletz S., Baumeister H., et al. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother 55 12 (2006) 1480-1490
21. Holtl L., Ramoner R., Zelle-Rieser C., Gander H., Putz T., Papesh C., et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54 7 (2005) 663-670
22. Neves A.R., Ensina L.F., Anselmo L.B., Leite K.R., Buzaid A.C., Camara-Lopes L.H., et al. Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother 54 1 (2005) 61-66
23. Hus I., Rolinski J., Tabarkiewicz J., Wojas K., Bojarska-Junak A., Greiner J., et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19 9 (2005) 1621-1627
24. + T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leuk Res 28 5 (2004) 517-524
25. McCutcheon M., Wehner N., Wensky A., Kushner M., Doan S., Hsiao L., et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 210 2 (1997) 149-166
26. Lee J.J., Park M.S., Park J.S., Kang H.K., Kim S.K., Nguyen Pham T.N., et al. Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens. J Clin Apher 21 3 (2006) 188-194
27. Narita M., Takahashi M., Liu A., Nikkuni K., Furukawa T., Toba K., et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp Hematol 29 6 (2001) 709-719
28. Della Bella S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89 8 (2003) 1463-1472
29. Salcedo M., Bercovici N., Taylor R., Vereecken P., Massicard S., Duriau D., et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55 7 (2006) 819-829
30. Pandha H.S., John R.J., Hutchinson J., James N., Whelan M., Corbishley C., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94 3 (2004) 412-418
31. + T-cell immunity. J Immunother 29 5 (2006) 545-557
32. Mu L.J., Kyte J.A., Kvalheim G., Aamdal S., Dueland S., Hauser M., et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 93 7 (2005) 749-756